Crossmark

Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers

Crossref DOI link: https://doi.org/10.1038/s41440-022-01070-4

Published Online: 2022-10-20

Published Print: 2023-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Freeman, Mason W.

Bond, Mary

Murphy, Brian

Hui, James

Isaacsohn, Jonathan
License Information

Text and Data Mining valid from 2022-10-20

Version of Record valid from 2022-10-20
More Information

Article History

Received: 19 August 2022

Revised: 16 September 2022

Accepted: 28 September 2022

First Online: 20 October 2022

Compliance with ethical standards

:

: MF is an employee of CinCor Pharma, Inc. and receives stock-based compensation. JH is an employee of CinCor Pharma, Inc. and receives stock-based compensation. MB is an employee of and has equity in CinRx Pharma, LLC, which has an equity stake in CinCor Pharma, Inc. BM is an employee of and has equity in CinRx Pharma, LLC, which has an equity stake in CinCor Pharma, Inc. JI is an employee of and has equity in CinRx Pharma, LLC, which has an equity stake in CinCor Pharma, Inc.

: The trial was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonization. The study was conducted at Medpace Clinical Pharmacology Unit (Cincinnati, OH), with approval from the institutional review board, and all patients provided written informed consent before enrollment in the trial.

Document is current

Any future updates will be listed below